Oncolytic Virus Cancer Therapy Overview

Oncolytic virus (OV) cancer therapies are the virus based therapeutic strategies that infect and destroy cancer cells, and therefore act as an in situ cancer vaccine by releasing tumor-specific antigens. Viruses such as myxoma virus or reovirus have inherent selectivity to tumor cells, while being nonpathogenic to healthy human cells.

“Oncolytic Virus Cancer Therapy Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Oncolytic Virus Cancer Therapy Market.

The Oncolytic Virus Cancer Therapy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Oncolytic Virus Cancer Therapy Pipeline Report:

• Companies across the globe are diligently working toward developing novel Oncolytic Virus Cancer Therapy treatment therapies with a considerable amount of success over the years. Oncolytic Virus Cancer Therapy Key players such as – DNAtrix, Nouscom, Astellas Pharma, Transgene, Istari Oncology, DNAtrix, Targovax, Oncolytics Biotech, CG Oncolgy, and others, are developing therapies for the Oncolytic Virus Cancer Therapy treatment 

• Oncolytic Virus Cancer Therapy Emerging therapies such as – DNX 2440, NOUS PEV, ASP 9801, TG 6002, PVS-RIPO, DNX-2401, ONCOS 102, Pelareorep, CG0070, and others are expected to have a significant impact on the Oncolytic Virus Cancer Therapy market in the coming years.
• In September 2021 CG Oncology, Inc. announced a clinical trial collaboration to evaluate the safety and efficacy ofCG0070, an oncolytic immunotherapy, in combination with OPDIVO^® (nivolumab), Bristol Myers Squibb’s anti-PD-1therapy, for the treatment of metastatic urothelial cancer in a Phase 1/2 clinical study
• In October 2020 CG Oncology initiated a trial entitled as “A Phase 3 Study of CG0070 in PatientsWith Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus-Calmette-Guerin (BCG)”. The trial will get completed on January 2024 with an enrollment of 110 participants. The objective of this study is to evaluate the activity of intravesical (IVE) administration of CG0070 in patients with tissue pathology confirmed non-muscularinvasive bladder cancer (NMIBC) who have Bacillus-Calmette-Guerin (BCG) unresponsive disease, with either carcinoma in situ with or without Ta/T1 disease
• In December 2020, CG Oncology initiated a Phase II trial entitled as “Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette Guerin (CORE-001)”

Route of Administration

Oncolytic Virus Cancer Therapy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Intranasal
• Intravenous
• Oral
• Oral/Intravenous
• Parenteral
• Subcutaneous
• Subcutaneous/Intramuscular

Molecule Type

Products have been categorized under various Molecule types, such as

• Oncolytic Viruse

Oncolytic Virus Cancer Therapy Pipeline Therapeutics Assessment

• Oncolytic Virus Cancer Therapy Assessment by Product Type
• Oncolytic Virus Cancer Therapy By Stage and Product Type
• Oncolytic Virus Cancer Therapy Assessment by Route of Administration
• Oncolytic Virus Cancer Therapy By Stage and Route of Administration
• Oncolytic Virus Cancer Therapy Assessment by Molecule Type
• Oncolytic Virus Cancer Therapy by Stage and Molecule Type

DelveInsight’s Oncolytic Virus Cancer Therapy Report covers around 5+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Some of the key companies in the Oncolytic Virus Cancer Therapy Therapeutics Market include:

Key companies developing therapies for Oncolytic Virus Cancer Therapy are – Amgen, Oncolytics Biotech, Viralytics, Transgene SA, Oncolys BioPharma, Targovax, PsiOxus Therapeutics, SillaJen Biotherapeutics, Sorrento Therapeutics, Lokon Pharma, Genelux Corporation, Vyriad, TILT Biotherapeutics, Cold Genesys, and others.

Emerging Oncolytic Virus Cancer Therapy Drugs Under Different Phases of Clinical Development Include:

• DNX 2440: DNAtrix
• NOUS PEV: Nouscom
• ASP 9801: Astellas Pharma
• TG 6002 : Transgene
• PVS-RIPO: Istari Oncology
• DNX-2401: DNAtrix
• ONCOS 102: Targovax
• Pelareorep: Oncolytics Biotech
• CG0070: CG Oncolgy

Get a Free Sample PDF Report to know more about Oncolytic Virus Cancer Therapy Pipeline Therapeutic Assessment-

https://www.delveinsight.com/sample-request/oncolytic-virus-cancer-therapy-pipeline-insight-2021

Oncolytic Virus Cancer Therapy Pipeline Analysis:

The Oncolytic Virus Cancer Therapy pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Oncolytic Virus Cancer Therapy with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Oncolytic Virus Cancer Therapy Treatment.
• Oncolytic Virus Cancer Therapy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Oncolytic Virus Cancer Therapy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Oncolytic Virus Cancer Therapy market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Oncolytic Virus Cancer Therapy product details are provided in the report. Download the Oncolytic Virus Cancer Therapy pipeline report to learn more about the emerging Oncolytic Virus Cancer Therapy therapies

Oncolytic Virus Cancer Therapy Pipeline Market Drivers

• Increase in the number of patients with cancers
• Rising need for advanced and effective cancer therapeutics for improved quality of life

Oncolytic Virus Cancer Therapy Pipeline Market Barriers

• Lack of development, scaleup and commercialisation resources available to developers
• Lack of awareness about the new class of anticancer immunotherapy

Scope of Oncolytic Virus Cancer Therapy Pipeline Drug Insight    

• Coverage: Global
• Key Oncolytic Virus Cancer Therapy Companies: DNAtrix, Nouscom, Astellas Pharma, Transgene, Istari Oncology, DNAtrix, Targovax, Oncolytics Biotech, CG Oncolgy, and others
• Key Oncolytic Virus Cancer Therapy Therapies: DNX 2440, NOUS PEV, ASP 9801, TG 6002, PVS-RIPO, DNX-2401, ONCOS 102, Pelareorep, CG0070, and others
• Oncolytic Virus Cancer Therapy Therapeutic Assessment: Oncolytic Virus Cancer Therapy current marketed and Oncolytic Virus Cancer Therapy emerging therapies
• Oncolytic Virus Cancer Therapy Market Dynamics: Oncolytic Virus Cancer Therapy market drivers and Oncolytic Virus Cancer Therapy market barriers 

Request for Sample PDF Report for Oncolytic Virus Cancer Therapy Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report to know more about Oncolytic Virus Cancer Therapy drugs and therapies

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/r-and-d-analysis